RESUMEN
Immunomodulation uses synthetic, natural and recombinant preparations to modify the immune response to a desired level, typically to treat specific autoimmune diseases, as will be discussed in this section. Rheumatoid arthritis (RA) is a common systemic autoimmune disease, affecting 1% of the population worldwide. Currently, a first-line disease-modifying therapy for RA is methotrexate; however, more than 40 monoclonal antibodies are in use or under investigation for the treatment of RA. This panoply of biological disease-modifying agents means that clinicians can make use of drugs with different mechanisms of action should one type become ineffective. In autoimmune pemphigus conditions, identification of pathogenic autoantibodies against intercellular cadherin desmoglein 1 and/or 3 antigens is one of the criteria for appropriate diagnosis. In pemphigoid conditions, autoantibodies are directed against bullous pemphigoid antigens BP230 and BP180, and in both types of immunobullous disease intravenous immunoglobulin (IVIg), as adjuvant therapy in combination with a cytotoxic drug, is effective in reducing autoantibody levels, disease severity and background steroid use. Further studies are required to establish the role of monoclonal antibodies in the treatment of autoimmune bullous disease. IVIg may also be effective in another at-risk population with autoimmune disease, namely secondary recurrent miscarriage (RM). However, the mechanism of action of IVIg in secondary RM is largely unknown, although levels of natural killer cell biomarkers, particularly CD56(+) , have been shown to decline after IVIg treatment. Data from meta-analyses of heterogeneous placebo-controlled trials indicate that IVIg may be effective in secondary RM, but most trials to date have used immunomodulatory doses lower than those considered to be efficient in autoimmune disease. The results of a recently completed study may help to address this question.
Asunto(s)
Inmunoglobulinas Intravenosas/inmunología , Inmunomodulación/inmunología , Autoanticuerpos/inmunología , Enfermedades Autoinmunes/inmunología , Antígeno CD56/inmunología , Ensayos Clínicos como Asunto , Humanos , Metaanálisis como AsuntoRESUMEN
Rheumatoid arthritis (RA) is a debilitating autoimmune disease that is usually treated aggressively to slow the rate of joint destruction. The therapeutic strategy used at the French centre, described here, is to use the non-biological disease-modifying drug, methotrexate, as first-line therapy and to add biological agents as second-line treatment. The two other autoimmune diseases discussed in this session were immunobullous skin diseases, and secondary recurrent miscarriage (RM). In the former conditions, low levels of pathogenic autoantibodies can be achieved with adjuvant intravenous immunoglobulin (IVIg) therapy, usually in combination with an immunosuppressant. Secondary RM has an autoimmune basis, as shown by high tumour necrosis factor (TNF)-α levels and specific human leucocyte antigen (HLA) polymorphisms. Although the mechanism is not yet known, IVIg may also be an effective treatment, despite the generally low doses used in published studies.
Asunto(s)
Inmunoglobulinas Intravenosas/inmunología , Inmunoglobulinas Intravenosas/uso terapéutico , Aborto Habitual/inmunología , Aborto Habitual/terapia , Artritis Reumatoide/inmunología , Artritis Reumatoide/terapia , Autoanticuerpos/inmunología , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/terapia , Antígenos HLA/inmunología , Humanos , Inmunización Pasiva/métodos , Inmunosupresores/inmunología , Inmunosupresores/uso terapéutico , Factor de Necrosis Tumoral alfa/inmunologíaRESUMEN
OBJECTIVE: To update the follow-up of the Euro-Lupus Nephritis Trial (ELNT), a randomised prospective trial comparing low-dose (LD) and high-dose (HD) intravenous (IV) cyclophosphamide (CY) followed by azathioprine (AZA) as treatment for proliferative lupus nephritis. PATIENTS AND METHODS: Data for survival and kidney function were prospectively collected during a 10-year period for the 90 patients randomised in the ELNT, except in 6 lost to follow-up. RESULTS: Death, sustained doubling of serum creatinine and end-stage renal disease rates did not differ between the LD and HD group (5/44 (11%) vs 2/46 (4%), 6/44 (14%) vs 5/46 (11%) and 2/44 (5%) vs 4/46 (9%), respectively) nor did mean serum creatinine, 24 h proteinuria and damage score at last follow-up. Most patients in both groups were still treated with glucocorticoids, other immunosuppressant agents and blood pressure lowering drugs. After 10 years of follow-up, the positive predictive value for a good outcome of an early drop in proteinuria in response to initial immunosuppressive therapy was confirmed. CONCLUSION: The data confirm that a LD IVCY regimen followed by AZA-the "Euro-Lupus regimen"-achieves good clinical results in the very long term.
Asunto(s)
Ciclofosfamida/administración & dosificación , Inmunosupresores/administración & dosificación , Nefritis Lúpica/tratamiento farmacológico , Adolescente , Adulto , Azatioprina/uso terapéutico , Ciclofosfamida/uso terapéutico , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Métodos Epidemiológicos , Femenino , Humanos , Inmunosupresores/uso terapéutico , Inyecciones Intravenosas , Pruebas de Función Renal , Nefritis Lúpica/fisiopatología , Masculino , Persona de Mediana Edad , Proteinuria/tratamiento farmacológico , Resultado del Tratamiento , Adulto JovenRESUMEN
The posters presented at the 6th International Immunoglobulin Symposium covered a wide range of fields and included both basic science and clinical research. From the abstracts accepted for poster presentation, 12 abstracts were selected for oral presentations in three parallel sessions on immunodeficiencies, autoimmunity and basic research. The immunodeficiency presentations dealt with novel, rare class-switch recombination (CSR) deficiencies, attenuation of adverse events following IVIg treatment, association of immunoglobulin (Ig)G trough levels and protection against acute infection in patients with X-linked agammaglobulinaemia (XLA) and common variable immunodeficiency (CVID), and the reduction of class-switched memory B cells in patients with specific antibody deficiency (SAD). The impact of intravenous immunoglobulin on fetal alloimmune thrombocytopenia, pregnancy and postpartum-related relapses in multiple sclerosis and refractory myositis, as well as experiences with subcutaneous immunoglobulin in patients with multi-focal motor neuropathy, were the topics presented in the autoimmunity session. The interaction of dendritic cell (DC)-SIGN and alpha2,6-sialylated IgG Fc and its impact on human DCs, the enrichment of sialylated IgG in plasma-derived IgG, as wells as prion surveillance and monitoring of anti-measles titres in immunoglobulin products, were covered in the basic science session. In summary, the presentations illustrated the breadth of immunoglobulin therapy usage and highlighted the progress that is being made in diverse areas of basic and clinical research, extending our understanding of the mechanisms of immunoglobulin action and contributing to improved patient care.
Asunto(s)
Inmunoglobulinas/uso terapéutico , Síndromes de Inmunodeficiencia/tratamiento farmacológico , Enfermedades Autoinmunes/tratamiento farmacológico , Autoinmunidad/inmunología , Investigación Biomédica , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Síndromes de Inmunodeficiencia/inmunologíaRESUMEN
OBJECTIVE: The aim of this study was to investigate potential risk factors for Sjögren's syndrome (SS) by means of a multi-centre case-control study, focusing in particular on familial and environmental risk factors. 140 female SS patients and 109 female controls with orthopaedic problems were consecutively enrolled in seven university hospitals in Italy. METHODS: Information regarding the patient's lifestyle, her medical, menstrual and pregnancy history, and any family history of autoimmune diseases (AD) was obtained through a detailed structured questionnaire. The odds ratio (OR) and 95% confidence interval (95%CI) were calculated using unconditional logistic regression, adjusting for age and family size. The probability of first-degree relatives developing an autoimmune disease was also investigated. RESULTS: A positive family history of AD was significantly associated with SS. Subjects with a first-degree relative (FDR) with AD showed a seven-fold increase in the risk for SS compared to controls (OR=7.4, 95%CI 2.8-20.1); the strength of this association increased with the number of relatives affected. Similarly, the FDR of SS patients had a higher risk of AD in comparison to subjects without FDR affected by SS. Women with one or more pregnancies had an increased risk of SS (OR=2.1, 95%CI 1.0-4.3). CONCLUSION: This study suggests that a family history of AD is associated with SS.
Asunto(s)
Historia Reproductiva , Síndrome de Sjögren/genética , Adulto , Anciano , Enfermedades Autoinmunes/etiología , Estudios de Casos y Controles , Femenino , Encuestas Epidemiológicas , Humanos , Estilo de Vida , Modelos Logísticos , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Linaje , Factores de Riesgo , Síndrome de Sjögren/epidemiología , FumarRESUMEN
The "Euro-Lupus Cohort" is composed by 1000 patients with systemic lupus erythematosus (SLE) that have been followed prospectively since 1991. These patients have been gathered by a European consortium--the "Euro-Lupus Project Group". This consortium was originated as part of the network promoted by the "European Working Party on SLE", a working group created in 1990 in order to promote research in Europe on the different problems related to this disease. The "Euro-Lupus Cohort" provides an updated information on the SLE morbidity and mortality characteristics in the present decade as well as defines several clinical and immunological prognostic factors.
Asunto(s)
Enfermedades Autoinmunes/diagnóstico , Enfermedades Autoinmunes/epidemiología , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/epidemiología , Edad de Inicio , Anticuerpos Antinucleares/sangre , Enfermedades Autoinmunes/sangre , Enfermedades Autoinmunes/mortalidad , Estudios de Cohortes , Europa (Continente)/epidemiología , Femenino , Estudios de Seguimiento , Humanos , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/mortalidad , Masculino , Morbilidad , Pronóstico , Estudios Prospectivos , Tasa de SupervivenciaRESUMEN
OBJECTIVE: To study those conditions with a proven or hypothesised immunologic pathogenesis and denominated under a working definition of undifferentiated connective tissue diseases (UCTD). METHODS: A multicentre prospective study was organised involving 10 tertiary referral centers of internal medicine in Italy, with the aim of describing the natural history of UCTD and the prevalence of its different clinical and immunological manifestations. RESULTS: After a five-year follow-up period, data on 165 patients were available for analysis. UCTDs occur mainly in females in their fourth decade of life. Articular and mucocutaneous features and Raynaud's phenomenon represent the most common findings. Nevertheless, we also detected a relatively high incidence of permanent major organ damage. Regarding the immunologic parameters, we documented some conflicting results in the correlation between serologic abnormalities and clinical features. In 10 patients UCTD evolved to a major disease, generally systemic lupus erythematosus or Sjögren's syndrome. CONCLUSION: A low rate of evolution to a defined autoimmune disease, the limited use of steroid or immunosuppressive therapy, and a favourable course in the majority of cases are the main characteristics of patients with UCTDs.
Asunto(s)
Antiinflamatorios/administración & dosificación , Enfermedades del Tejido Conjuntivo/tratamiento farmacológico , Enfermedades del Tejido Conjuntivo/inmunología , Adolescente , Adulto , Anciano , Anticuerpos Antinucleares/análisis , Enfermedades Autoinmunes/tratamiento farmacológico , Enfermedades Autoinmunes/inmunología , Progresión de la Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Italia , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Enfermedad de Raynaud/tratamiento farmacológico , Enfermedad de Raynaud/inmunología , Esteroides , Resultado del Tratamiento , Vasculitis/tratamiento farmacológico , Vasculitis/inmunologíaRESUMEN
A complete understanding of the molecular features of humoral immune response could be of pivotal importance in the management of persistent viruses as HCV. In this study, 24 HCV-positive samples, characterized by classical virological parameters, are evaluated using a new assay for the quantitation of antibody subpopulations directed against discrete epitopes on surface glycoprotein E2, a key viral protein. The results, besides confirming the usefulness of this new approach, highlight the extreme heterogeneity of anti-HCV/E2 response as far as single epitopes are concerned. The specific epitopes under study are also demonstrated to be widely shared among different genotypes.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Hepacivirus/inmunología , Anticuerpos contra la Hepatitis C/inmunología , Proteínas del Envoltorio Viral/inmunología , Anticuerpos Monoclonales/genética , Formación de Anticuerpos/inmunología , Unión Competitiva/inmunología , Ensayo de Inmunoadsorción Enzimática/métodos , Epítopos/inmunología , Genotipo , Hepacivirus/genética , Hepatitis C/diagnóstico , Hepatitis C/inmunología , Anticuerpos contra la Hepatitis C/sangre , Anticuerpos contra la Hepatitis C/genética , Antígenos de la Hepatitis C/inmunología , Humanos , Fragmentos Fab de Inmunoglobulinas/genética , Fragmentos Fab de Inmunoglobulinas/inmunología , Modelos Inmunológicos , Oligopéptidos , Péptidos/genética , Péptidos/inmunología , Proteínas Recombinantes/genética , Proteínas Recombinantes/inmunología , Carga Viral/métodosRESUMEN
Connective tissue diseases (CTDs) are chronic multisystemic inflammatory disorders whose indicative signs or symptoms have a high sensitivity but poor specificity in predicting the evolution into a given CTD. We have analysed 84 consecutive patients initially diagnosed as having an early undifferentiated CTD (early UCTD) with the aim of verifying the evolution into one definite CTD and of evaluating the predictive value of clinical and laboratory parameters. During a 5-year study period, 33 patients developed signs of a full-blown CTD; the highest probability of evolution was in the first 48 months after the onset. Multivariate analysis allowed us to select those variables correlating with evolution into a particular CTD, such as sclerodactyly and oesophageal dysfunction for systemic sclerosis, xerostomia and anti-nuclear antibodies (SS-A pattern) for Sjögren's syndrome, and fever and anti-DNA antibodies for systemic lupus erythematosus. Furthermore, we assessed the prevalence of various clinical and laboratory manifestations, complications and prognosis of those patients diagnosed after a 5-year disease duration period as having a UCTD. In our series, major organs such as the kidney or heart seem to be spared, whereas we detected a relatively high prevalence of endocrine disease of autoimmune origin.
Asunto(s)
Enfermedades del Tejido Conjuntivo/diagnóstico , Adolescente , Adulto , Anciano , Análisis de Varianza , Enfermedades del Tejido Conjuntivo/inmunología , Enfermedades del Tejido Conjuntivo/terapia , Diagnóstico Diferencial , Progresión de la Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/inmunología , Masculino , Persona de Mediana Edad , Enfermedad Mixta del Tejido Conjuntivo/diagnóstico , Enfermedad Mixta del Tejido Conjuntivo/inmunología , Valor Predictivo de las Pruebas , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Esclerodermia Sistémica/diagnóstico , Esclerodermia Sistémica/inmunología , Resultado del TratamientoRESUMEN
Previous data have indicated that organ-specific and non-organ-specific autoimmune diseases may occur in the same patient. We report here our study on the type and prevalence of endocrine autoimmune diseases in undifferentiated connective tissue disease (UCTD). A retrospective analysis revealed five out of 75 UCTD cases (6.6%) with cytology-verified autoimmune thyroiditis (associated with insulin-dependent diabetes mellitus in one case). Other UCTD patients had Graves' disease (one case), non-toxic multinodular goitre (two cases) and central hypothyroidism (one case). In a prospective study, thyroid function was evaluated in 15 consecutive UCTD patients with neither clinical nor laboratory signs of thyroid involvement. Basal and post-TRH stimulation TSH levels were significantly higher in UCTD patients than in healthy subjects.
Asunto(s)
Enfermedades del Tejido Conjuntivo/complicaciones , Proteínas de Unión a Hierro , Tiroiditis Autoinmune/complicaciones , Adolescente , Adulto , Anciano , Anticuerpos Antinucleares/inmunología , Autoantígenos/inmunología , Biopsia con Aguja , Enfermedades del Tejido Conjuntivo/diagnóstico , Enfermedades del Tejido Conjuntivo/inmunología , Diagnóstico Diferencial , Femenino , Técnica del Anticuerpo Fluorescente , Humanos , Yoduro Peroxidasa/inmunología , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Radioinmunoensayo , Estudios Retrospectivos , Tiroglobulina/inmunología , Tiroiditis Autoinmune/sangre , Tiroiditis Autoinmune/diagnóstico , Tiroiditis Autoinmune/inmunología , Tirotropina/sangreRESUMEN
New data emphasize the importance of nutritional factors in autoimmune diseases. Dietary alterations can be linked to autoimmune disorders as a specific pathogenetic mechanism and also for the malnutrition conditions frequently documented in these patients. The precise function of different nutrients is not completely known as they can be primary pathogenetic agents or causes of acute reacerbations or, finally, simply accompanying phenomena. It is also difficult to modify the intake of a single dietary component and to clarify its metabolic importance for the complexity of metabolic events in the human body and for the possible appearance of cascade-mechanisms. In lipid metabolism the multiple interactions between fatty acids, prostaglandins and leukotrienes are linked to alterations in inflammatory parameters. The exact role of modifications of proteins or of a single amino acid on immune function, also for the possible interference in protein restricted diet of the caloric component, is still unknown. Trace elements and vitamins are certainly important for the control of inflammation and of susceptibility in infections, albeit their role is not clear. More studies are necessary to clarify the link between dietary component and autoimmune diseases. However, study in experimental models and in human Systemic Lupus Erythematosus and Rheumatoid Arthritis demonstrated that a good nutritional homeostasis can contribute to decrease the severity of these disorders and to modify the clinical course with a physiological treatment that is free of side effects.
Asunto(s)
Enfermedades Autoinmunes , Dieta , Animales , Antígenos , Enfermedades Autoinmunes/etiología , Enfermedades Autoinmunes/inmunología , Grasas de la Dieta/farmacología , Proteínas en la Dieta/farmacología , Ingestión de Energía , Etanol/farmacología , Humanos , Ratones , Ratas , Oligoelementos/farmacología , Vitaminas/farmacologíaRESUMEN
Rheumatoid arthritis (RA) is a chronic multisystemic disease affecting mainly the joints and characterised by a poor prognosis. In a four month open study we evaluated the efficacy and tolerability of a combination therapy in 14 patients with active and refractory RA (non responsive to MTX or CsA monotherapy). After three pulses of methyl-prednisolone (125 mg/die i.v. for 3 days), at day the 4 patients received methotrexate (MTX 15/mg/week p.os) and cyclosporine (CsA 3 mg/kg/day p.os). At the end of treatment period, patients had a statistically significant improvement in the tender-joint count (Ritchie Index) in the swollen-joint count and in the pain as recorded on a 100-mm visual-analogue scale. Following the criteria of the American College of Rheumatology for response to treatment in RA, 6 patients (60%) met these criteria, whereas 2 had a worsening. We could not detect any clear difference in serological parameters (ESR, CRP and Hb levels) between the beginning and the end of the therapy. A significant difference in the score of edema/joint effusion was documented at the RM analysis. Side-effects were not substantially increased as compared to MTX or CsA in single therapy. Combination therapy with CsA and MTX seems to be a safe and effective treatment for patients with active and refractory RA.
Asunto(s)
Antirreumáticos/administración & dosificación , Artritis Reumatoide/tratamiento farmacológico , Ciclosporina/administración & dosificación , Metotrexato/administración & dosificación , Antiinflamatorios/uso terapéutico , Artritis Reumatoide/diagnóstico , Interpretación Estadística de Datos , Quimioterapia Combinada , Humanos , Imagen por Resonancia Magnética , Metilprednisolona/administración & dosificación , Factores de TiempoRESUMEN
In this paper we considered different models concerning the clinical expression of neuropsychiatric involvement in course of systemic lupus erythematosus (SLE). These models describe pathological conditions as multifocal cerebropathy, transverse myelitis, peripheral neuropathy and panic attacks. We have chosen these cases as clinical example of different pathogenic mechanisms responsible of CNS-lupus, as hypercoagulation due to antiphospholipid syndrome, immune-complex vasculitis, complement-mediated autoantibody damage and antibody-induced cytotoxicity. The prevalence of neuropsychiatric manifestations in 122 SLE patients is also reported. Finally, the paper reports some guidelines about diagnostic and therapeutic behaviour in course of CNS-lupus.
Asunto(s)
Lupus Eritematoso Sistémico/complicaciones , Enfermedades del Sistema Nervioso/etiología , Adolescente , Resultado Fatal , Femenino , Humanos , Embolia y Trombosis Intracraneal/diagnóstico , Embolia y Trombosis Intracraneal/etiología , Italia/epidemiología , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/epidemiología , Masculino , Persona de Mediana Edad , Mielitis Transversa/diagnóstico , Mielitis Transversa/etiología , Enfermedades del Sistema Nervioso/diagnóstico , Enfermedades del Sistema Nervioso/epidemiología , Trastorno de Pánico/diagnóstico , Trastorno de Pánico/etiología , Polirradiculoneuropatía/diagnóstico , Polirradiculoneuropatía/etiología , PrevalenciaAsunto(s)
Linfocitos B/clasificación , Disgammaglobulinemia/inmunología , Deficiencia de IgA , Linfocitos T/clasificación , Linfocitos B/análisis , Linfocitos B/inmunología , Niño , Preescolar , Femenino , Humanos , Deficiencia de IgG , Inmunidad Celular , Inmunoglobulina M/deficiencia , Lactante , Recuento de Leucocitos , Masculino , Linfocitos T/análisis , Linfocitos T/inmunologíaAsunto(s)
Artritis Reumatoide/diagnóstico , Adolescente , Adulto , Anciano , Anticuerpos Antinucleares/análisis , Complejo Antígeno-Anticuerpo/análisis , Niño , Colágeno/inmunología , Proteínas del Sistema Complemento/análisis , Humanos , Pruebas de Fijación de Látex , Persona de Mediana Edad , Factor Reumatoide/análisis , Líquido Sinovial/análisisRESUMEN
OBJECTIVE: To test the association of osteopontin (OPN) polymorphisms with systemic lupus erythematosus (SLE). METHODS: The coding 5' and 3' flanking regions of the OPN gene were scanned for polymorphisms by denaturing high-performance liquid chromatography. A case-control association study was performed in 394 Italian SLE patients and 479 matched controls. OPN serum levels were determined by enzyme-linked immunosorbent assay in 40 patients and 124 controls, and the mean levels were compared between the different OPN genotypes. RESULTS: Among the 13 detected single-nucleotide polymorphisms (SNPs), alleles -156G (frequency 0.714 versus 0.651; P = 0.006, corrected P [P(corr)] = 0.036) and +1239C (0.377 versus 0.297; P = 0.00094, P(corr) = 0.0056) were significantly increased in the SLE patients compared with the controls. The presence of the associated allele in single or double dose conferred an odds ratio (OR) of 2.35 (95% confidence interval [95% CI] 1.38-4.02) for SNP -156 and an OR of 1.57 (95% CI 1.16-2.13) for SNP +1239. These effects were independent of each other, i.e., not a consequence of linkage disequilibrium between the 2 alleles. The risk associated with a double dose of susceptibility alleles at both SNPs was 3.8-fold higher (95% CI 2.0-7.4) relative to the complete absence of susceptibility alleles. With regard to individual clinical and immunologic features, a significant association was seen between lymphadenopathy and -156 genotypes (overall P = 0.0011, P(corr) = 0.046). A significantly increased OPN serum level was detected in healthy individuals carrying +1239C (P = 0.002), which is indicative of an association between the SLE susceptibility allele and OPN levels. CONCLUSION: These data suggest the independent effect of a promoter (-156) and a 3'-untranslated region (+1239) SNP in SLE susceptibility. We can speculate that these sequence variants (or others in perfect linkage disequilibrium) create a predisposition to high production of OPN, and that this in turn may confer susceptibility to SLE.
Asunto(s)
Susceptibilidad a Enfermedades , Lupus Eritematoso Sistémico/genética , Polimorfismo de Nucleótido Simple , Sialoglicoproteínas/genética , Femenino , Humanos , Masculino , Osteopontina , Sialoglicoproteínas/sangreRESUMEN
OBJECTIVE: To study the long term effectiveness of intravenous immunoglobulin and plasmapheresis associated with prednisone and cyclophosphamide in Churg-Strauss syndrome. SUBJECTS: and methods: We studied 18 subjects with new onset Churg-Strauss syndrome. All received the "standard" treatment based on prednisone (1 mg/kg/day for 1 month and then slowly tapered) and cyclophosphamide (2 mg/kg/day for 6 months in severe cases). In nine patients, synchronised cycles with plasmapheresis and intravenous immunoglobulin (2 g/kg) were repeated monthly for 6 months and every other month for a further three cycles. Clinical (disease activity monitored by Birmingham vasculitis activity score (BVAS) and damage index (modified Rankin score)) and functional (C reactive protein, blood eosinophil count, and electromyogram-electoneurogram) parameters were collected during treatment and the 3 year follow up period. RESULTS: After 12 months, all patients in the treatment group and four (44%) in the control group were in remission. At the end of the 3 year follow up period, we documented significant differences in BVAS (p<0.01), global damage (p<0.02), modified Rankin score (p<0.04), and the daily maintenance prednisone dose (p<0.002) between the two groups. We found a tendency towards lower frequency of relapse and incidence of osteoporosis in the treatment group. CONCLUSION: Complete clinical and functional recovery with a long term stable remission and a low incidence of side effects can be achieved by intravenous immunoglobulin associated with plasmapheresis in patients with Churg-Strauss syndrome.
Asunto(s)
Síndrome de Churg-Strauss/terapia , Inmunoglobulinas Intravenosas/uso terapéutico , Adulto , Anciano , Terapia Combinada , Ciclofosfamida/uso terapéutico , Evaluación de Medicamentos , Femenino , Estudios de Seguimiento , Glucocorticoides/uso terapéutico , Humanos , Inmunoglobulinas Intravenosas/efectos adversos , Inmunosupresores/uso terapéutico , Masculino , Persona de Mediana Edad , Plasmaféresis/efectos adversos , Plasmaféresis/métodos , Prednisona/uso terapéutico , Estudios Prospectivos , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
Soluble interleukin 2 receptor (sIL2R) may be used as an index of immune perturbation. We report on the correlation between the serum levels of sIL2R, as assessed with a sandwich-ELISA, and disease activity in 61 patients with Systemic Lupus Erythematosus (SLE) and in 15 with systemic idiopathic vasculitis (SIV). The mean levels of sIL2R in SLE and SIV patients were significantly higher than in healthy controls and higher values were detected in patients with active disease or severe organ involvement or infection. We also studied patients with clinically silent SLE, characterized by the presence of several immunologic abnormalities. The sIL2R mean level in this group did not differ from that of quiescent SLE patients, suggesting that immunologic alterations are present even in inactive SLE. Finally, the sIL2R assay showed higher sensitivity and specificity than most of the common immunologic parameters.
Asunto(s)
Lupus Eritematoso Sistémico/sangre , Receptores de Interleucina-2/análisis , Índice de Severidad de la Enfermedad , Vasculitis/sangre , Adolescente , Adulto , Anciano , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Sensibilidad y EspecificidadAsunto(s)
Calcinosis/etiología , Lupus Eritematoso Sistémico/complicaciones , Enfermedades del Bazo/etiología , Adulto , Calcinosis/diagnóstico , Calcinosis/epidemiología , Diagnóstico Diferencial , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Prevalencia , Radiografía Abdominal , Estudios Retrospectivos , Bazo/diagnóstico por imagen , Bazo/patología , Enfermedades del Bazo/diagnóstico , Enfermedades del Bazo/epidemiología , UltrasonografíaRESUMEN
We report on a case of a 17-year-old female with systemic lupus erythematosus (SLE), with a clinical history of complex partial seizure, who developed a tonicoclonic crisis after receiving hydroxychloroquine for 2 weeks at a dosage of 200 mg/day (5 mg/kg). The absence of previous similar episodes and of recurrences after withdrawal of the drug in subsequent months, the short latency after administration and the favourable short-term evolution raised suspicions for a potential role of the drug in the development of the isolated convulsive crisis. It is possible for hydroxychloroquine to be responsible for tonicoclonic seizures in predisposed subjects.